{
    "nct_id": "NCT04702880",
    "official_title": "A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC) and extensive-stage disease (American Joint Committee on Cancer, 8th edition, Stage IV [T any, N any, M1a, M1b, or M1c], or T3-4 due to multiple lung nodules that are too extensive or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan)\n* Participants taking part in the separate PET tracer sub-study must provide a fresh tumor biopsy from any disease site (primary or metastatic)\n* Archived tumor specimens, in the form of blocks or sectioned slides, are mandatory for all participants except those participating in the separate PET tracer sub-study for whom the archived tumor specimen is optional\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1\n* At least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria\n* Adequate hematologic and end organ function\n* Must agree to follow specific methods of contraception, if applicable\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Women who are pregnant or breastfeeding. Japan only: participation in the study is not allowed even if breastfeeding is suspended\n* Prior chemotherapy, radiation therapy, or biologic therapy for SCLC. Previously treated limited stage SCLC (LS-SCLC) participants are also excluded\n* Symptomatic brain or other central nervous system (CNS) metastases\n* Paraneoplastic autoimmune syndrome requiring systemic treatment\n* History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan\n* Grade â‰¥ 2 peripheral sensory neuropathy at study entry\n* Significant uncontrolled cardiovascular disease\n* Active, known or suspected autoimmune disease or inflammatory disorder\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}